Clinical trials: Raynaud Phenomena
Raynaud's Phenomenon
Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon
This study represents the first trial to assess the efficacy of oral treprostinil therapy in patients with symptomatic primary or secondary Raynaud's Phenomenon (RP) resistant to vasodilatory therapy.
- Trial name
- NCT02583789
- Testing
- oral treprostinil
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Brigham and Women's Hospital
Raynaud's Disease
Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
Juvenile secondary Raynaud's (ray-knows) Phenomenon is a disorder of the blood vessels in the fingers and sometimes can affect the toes, nose, or ears.
- Trial name
- NCT00048776
- Testing
- Pletal
- Where
- 19 sites in United States
- Volunteers
- 75 people
- Sponsor
- Otsuka America Pharmaceutical
Raynaud Phenomenon
Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon
The prevalence of Raynaud phenomenon (RP), a reversible vaso-constriction with skin discoloration, is 5-10% in general population.
- Trial name
- NCT01280266
- Testing
- Udenafil or Amlodipine
- Where
- South Korea
- Volunteers
- 29 people
- Sponsor
- Seoul National University Hospital
Systemic Sclerosis
CSL Behring Sclero XIII
Many patients with Scleroderma (Systemic sclerosis) experience damage to blood vessels, mainly to the small arteries. A common manifestation of this is Raynaud's phenomenon (fingers or toes turning white then blue in the cold)…
- Trial name
- NCT02551042
- Testing
- Fibrogammin®P, coagulation factor XIII concentrate (Human), 0.9% sodium chloride
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- University College, London
Raynaud's Phenomenon, Skin Necrosis
Prognostic Influence of Light Rheography Measurement of Patients With Secondary Raynaud Syndrome With Ulcers on Hands
The purpose of this study is to evaluate the prognostic influence of light rheography measurement at the fingertips from subjects with secundary Raynaud syndrome.
- Trial name
- Anti-Vasospasm (NCT01378845)
- Testing
- Tracleer, Prostavasin
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Christoph Hehrlein
Raynaud Phenomenon
Botulinum Toxin in Raynaud's Phenomenon
Raynaud's Phenomenon (RP) is the most common vasospastic disorder encountered by hand surgeons with an estimated prevalence of 5% in the general population. It's manifestations are broad, and can range from minor to severe.
- Trial name
- NCT05125029
- Testing
- Botulinum toxin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Emory University
Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis
The purpose of this study is to determine whether oral temanogrel improves digital blood flow in participants with Raynaud's phenomenon secondary to systemic sclerosis (SSc-RP) as a potential safe and effective treatment for…
- Trial name
- NCT04915950
- Testing
- Temanogrel
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 13 people
- Sponsor
- Pfizer
Raynaud Disease
Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
In this double-blinded, placebo-controlled, fixed-dose, study patients will be randomly assigned to take placebo or 20 mg tadalafil thrice weekly for 6 weeks.
- Trial name
- NCT00626665
- Testing
- Tadalafil
- Volunteers
- 25 people
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
Raynaud's Disease
Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
Juvenile primary Raynaud's (ray-knows) Phenomenon is a disorder of the blood vessels in the fingers and sometimes can affect the toes, nose, or ears.
- Trial name
- NCT00048763
- Testing
- Pletal
- Where
- 18 sites in United States
- Volunteers
- 75 people
- Sponsor
- Otsuka America Pharmaceutical
Raynaud's Phenomenon
"As Required" Oral Sildenafil in Raynaud's Phenomenon
The purpose of this study is to determine whether "on-demand" sildenafil is effective in the treatment of Raynaud's phenomenon.
- Trial name
- PROFIL (NCT02050360)
- Testing
- Sildenafil 40 mg, Sildenafil 80 mg
- Where
- France
- Volunteers
- 41 people
- Sponsor
- University Hospital, Grenoble
Systemic Sclerosis, Fatigue
Apollo Device for Fatigue in Systemic Sclerosis
The purpose of this study is to learn about the effect of Apollo (a vibrating wearable about the side of an Apple Watch) on fatigue, Raynaud symptoms, depression, quality of life, and disease symptoms in patients with systemic…
- Conditions
- Systemic Sclerosis, Fatigue, Raynaud Phenomenon
- Trial name
- NCT04854850
- Testing
- Apollo
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Robyn T. Domsic, MD, MPH
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis
The primary objective of the study is to determine the activity of selexipag on Raynaud attack frequency in subjects with Raynaud's Phenomenon (RP) secondary to Systemic Sclerosis (SSc).
- Trial name
- NCT02260557
- Testing
- Selexipag
- Where
- 16 sites in France, Germany and 1 more
- Volunteers
- 74 people
- Sponsor
- Actelion
CREST Syndrome, Calcinosis Cutis
Localized Effects of PBM and Exogenous NO on CREST Patients Calcinosis Cutis & Raynaud Phenomenon
Background CREST is an acronym for the cardinal clinical features of the syndrome (Calcinosis, Raynaud phenomenon, Esophageal dysmotility, Sclerodactyly, and Telangiectasia) and part of the heterogeneous group of sclerodermas.
- Conditions
- CREST Syndrome, Calcinosis Cutis, Raynaud Phenomenon
- Trial name
- NCT03972566
- Testing
- INOMAX
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- RoseLab Skin Optics Laboratory
Raynaud Disease, Raynaud Phenomenon
Phototherapy For Treatment Of Raynaud's Phenomenon
To determine if blue light therapy can improve the symptoms of Raynaud's phenomenon, and provide parameters for ultimately designing commercial treatment devices, an investigational stationary phototherapy unit was designed and…
- Conditions
- Raynaud Disease, Raynaud Phenomenon, Raynaud Syndrome
- Trial name
- NCT04898036
- Testing
- Blue Light Therapy
- Where
- United States
- Sponsor
- University of Minnesota
Raynaud Phenomenon
Follow-up of SPTS in Patients With Raynaud's Phenomenon
Background: Raynaud's phenomenon is a vasospasm of the extremities, leading to extensive discomfort in daily life and potentially severe ischemia. Some patients are resistant to conventional vasodilatory drug treatment.
- Trial name
- NCT04015193
- Testing
- Single-port thoracoscopic sympathicotomy (patient care)
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- University Medical Center Groningen
Raynaud's Disease, Scleroderma
Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon
The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX-503) to relieve Raynaud's symptoms and increase blood flow to the fingers.
- Conditions
- Raynaud's Disease, Scleroderma, Autoimmune Diseases
- Trial name
- NCT00419419
- Testing
- Topical AmphiMatrix with nitroglycerin (MQX-503)
- Where
- 12 sites in United States, Sweden and 1 more
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- MediQuest Therapeutics
Scleroderma, Systemic Sclerosis
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
The primary objective of this study is to assess the safety and efficacy of the Celution Device in the processing of an autologous graft consisting of adipose derived regenerative cells (ADRCs) in the treatment of hand…
- Conditions
- Scleroderma, Systemic Sclerosis, Raynaud Phenomena, Raynaud's Disease
- Trial name
- STAR (NCT02396238)
- Testing
- Celution Device
- Where
- 19 sites in United States
- Volunteers
- 88 people
- Sponsor
- Cytori Therapeutics
Raynaud
Tadalafil for the Treatment of Raynaud's
The investigators propose that tadalafil will increase digital blood flow and improve the symptoms and signs of secondary Raynaud's phenomenon.
- Trial name
- NCT00822354
- Testing
- Tadalafil
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwestern University
Raynaud's Disease
Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon
The purpose of this clinical study is to determine the response to two different dosage strengths of a topical nitroglycerin gel in patients with Raynaud's Phenomenon.
- Trial name
- NCT00480753
- Testing
- Nitroglycerin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- MediQuest Therapeutics
Systemic Sclerosis (SSc)
The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life
The purpose of this study it to test the efficacy of a wearable device to improve symptom management and maximize qualify of life in systemic Sclerosis (SSc) patients in a randomized trial.
- Trial name
- ASScERT-QoL (NCT06675344)
- Testing
- Apollo Neuro Device
- Where
- 4 sites in United States
- Volunteers
- 160 people
- Sponsor
- Robyn T. Domsic, MD, MPH